ArticleFrontiers in medicine2025
Network pharmacology, molecular docking and
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Psoriasis remains incurable, driving the need for new treatments. This study evaluated the therapeutic effects of oleanolic acid on IMQ-induced psoriasis model mice and used network pharmacology and molecular docking to predict its mechanism of action. Methods: This study assessed the different concentrations (1%, 5%, 10%) of oleanolic acid cream effects on IMQ-induced psoriasis in female BALB/c mice, evaluating therapeutic outcomes via PASI scores, skin lesion staining, and inflammatory factor detection. Network pharmacology and molecular docking predicted OA's mechanism. Key targets were identified using databases and software analyses. Results: Oleanolic acid can treat skin damage in psoriasis model mice and improve systemic inflammatory responses. Network pharmacology results identified important potential targets for OA treatment of psoriasis, including HSP90AA1, STAT3, MAPK3, HSP90AB1, PPARG, PTGS2, AR, CDK1. GO functional enrichment analysis involved biological functions such as inflammation response, signal transduction, G protein-coupled receptor signaling pathway, etc. KEGG pathway enrichment analysis involved signaling pathways such as neuroactive ligand-receptor interaction, PPAR signaling pathway, Th17 cell differentiation, etc. Molecular docking results showed good affinity between oleanolic acid and MAPK3, STAT3, AR, PPARG. Conclusion: Oleanolic acid has therapeutic effects on psoriasis, with possible target points being MAPK3, STAT3, AR, and PPARG, involving processes such as inflammation response, negative regulation of cell proliferation, and Th17 cell differentiation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.